Acromicric dysplasia due to a novel missense mutation in the fibrillin 1 gene in a three-generation family

2022/08/09 by Friederike Quitter, Monika Flury, Stephan Waldmueller +3
Biochemistry, Genetics and Molecular Biology · Medicine · #Bone health and treatments #Connective tissue disorders research #Ubiquitin and proteasome pathways

paper · doi:10.1515/jpem-2022-0287

openalex publication_date 2022/08/09 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/23

Abstract

Abstract Objectives Short stature is one of the most common reasons for consulting a paediatric endocrinologist. Targeted diagnosis of familial short stature can be challenging due to a broad spectrum of differential diagnoses. Case presentation Here we report a novel mutation in the fibrillin 1 gene (FBN1) in six family members causing a mild phenotype of acromicric dysplasia. Additionally, we present the effects of growth hormone therapy in one of the affected children. Conclusions Acromicric dysplasia is a very rare skeletal dysplasia with a prevalence of <1 of 1.000.000 with only about 60 cases being reported worldwide. It is characterized by short stature, acromelia, mild facial dysmorphy but normal intelligence. This study aims to exemplify the clinical and molecular features of FBN1 -related acromicric dysplasia and illustrates its pleiotropy by presenting a new, mild phenotype.

Related

• Idiopathic short stature due to novel heterozygous mutation of the aggrecan gene
• A Novel Homozygous Mutation in FGFR3 Causes Tall Stature, Severe Lateral Tibial Deviation, Scoliosis, Hearing Impairment, Camptodactyly, and Arachnodactyly
• Severe Mandibuloacral Dysplasia-Associated Lipodystrophy and Progeria in a Young Girl with a Novel Homozygous Arg527Cys LMNA Mutation
• The KBG syndrome: follow‐up data on three affected brothers
• Short stature, craniofacial dysmorphism and dento‐skeletal abnormalities in a large kindred